AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11423841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 20% aminolevulinic acid hydrochloride (ALA) with optimal light dose of 10 J/cm²
Number of subjects: 36
Study 11423841 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment with light
Number of subjects: 36
Study 9015997 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric diabetes specialist nurse intervention
Number of subjects: 56
Study 9015997 — intervention group
Group type: COMPARATOR
Intervention: Standard care (before intervention)
Number of subjects: 56
Study 8278621 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo‐PGE1 (10 micrograms/day)
Number of subjects: 364
Study 8278621 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 364
Study 8278621 — intervention group
Group type: COMPARATOR
Intervention: PGE1‐CD (40 micrograms/day)
Number of subjects: 364
Study 8278621 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo‐PGE1
Number of subjects: 364
Study 8278621 — intervention group
Group type: COMPARATOR
Intervention: PGE1‐CD
Number of subjects: 364
Study 3318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering regimen of one week
Number of subjects: 43
Study 3318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering regimen of seven weeks
Number of subjects: 43
Study 3318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring mechanical ventilation
Number of subjects: 43
Study 3318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting more than two days of worse than usual dyspnea
Number of subjects: 43
Study 31863044 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal surface reduction on the treated tooth
Number of subjects: 44
Study 31863044 — intervention group
Group type: COMPARATOR
Intervention: No occlusal surface reduction (Control)
Number of subjects: 44
Study 30515481 — intervention group
Group type: EXPERIMENTAL
Intervention: Abutment group (received Multi-Unit Abutment, MUA)
Number of subjects: 32
Study 30515481 — intervention group
Group type: COMPARATOR
Intervention: No-abutment group (did not receive intermediate abutments)
Number of subjects: 32
Study 27016006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 0
Study 27016006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 25410507 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular stable locking system
Number of subjects: 142
Study 25410507 — intervention group
Group type: COMPARATOR
Intervention: Conventional locking screws
Number of subjects: 142
Study 22577172 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg rhTSH (n = 42)
Number of subjects: 86
Study 22577172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 86
Study 20979754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg/kg intravenously followed by 150 microg x kg(‐1) x min(‐1) intravenous infusion)
Number of subjects: 60
Study 20979754 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 18270313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 332
Study 18270313 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-control health promotion education
Number of subjects: 332
Study 18270313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332
Study 15465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS at 10 Hz (2000 pulses)
Number of subjects: 12
Study 15465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS at 0.5 Hz (600 pulses)
Number of subjects: 12
Study 15465443 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 12
Study 15465443 — intervention group
Group type: COMPARATOR
Intervention: Single dose of l-dopa
Number of subjects: 12
Study 11833926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (6-month, twice a week)
Number of subjects: 94
Study 11833926 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 94
Study 9893890 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44
Study 9893890 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 44
Study 7979119 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream (lidocaine and prilocaine), applied to the venepuncture site for at least 60 minutes.
Number of subjects: 60
Study 7979119 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, applied to the venepuncture site for at least 60 minutes.
Number of subjects: 60
Study 2481328 — intervention group
Group type: COMPARATOR
Intervention: MOPP/ABVD
Number of subjects: 0
Study 2481328 — intervention group
Group type: COMPARATOR
Intervention: ABVD plus radiotherapy
Number of subjects: 0
Study 2481328 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 0
Study 2481328 — intervention group
Group type: COMPARATOR
Intervention: MOPP plus radiotherapy
Number of subjects: 0
Study 864062 — intervention group
Group type: EXPERIMENTAL
Intervention: client-centered family approach
Number of subjects: 86
Study 864062 — intervention group
Group type: EXPERIMENTAL
Intervention: eclectic-dynamic approach
Number of subjects: 86
Study 864062 — intervention group
Group type: EXPERIMENTAL
Intervention: behaviorally oriented short-term family systems approach
Number of subjects: 86
Study 864062 — intervention group
Group type: EXPERIMENTAL
Intervention: family systems approach
Number of subjects: 86
Study 864062 — intervention group
Group type: COMPARATOR
Intervention: no treatment controls
Number of subjects: 86
Study 864062 — intervention group
Group type: COMPARATOR
Intervention: alternative treatment conditions
Number of subjects: 86
Study 30439609 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 939
Study 28328946 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy intervention (4-week program)
Number of subjects: 41
Study 28328946 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (4-week program)
Number of subjects: 41
Study 28328946 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy intervention (4-week program) after Standard Care
Number of subjects: 41
Study 25687540 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin application
Number of subjects: 110
Study 25687540 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin (control)
Number of subjects: 110
Study 23708138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative three-dimensional imaging (3D)
Number of subjects: 0
Study 23708138 — intervention group
Group type: COMPARATOR
Intervention: Computer assisted surgery (CAS)
Number of subjects: 0
Study 23708138 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative pedography (IP)
Number of subjects: 0
Study 21569574 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT for ≥10 months after PSA reached < 0.2 ng/ml
Number of subjects: 68
Study 21569574 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT (median duration 9 months)
Number of subjects: 68
Study 21569574 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant ADT (median duration 7.5 months)
Number of subjects: 68
Study 21569574 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery
Number of subjects: 68
Study 18394265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 18394265 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 17140281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone 40-80 mg twice daily for acute illness
Number of subjects: 0
Study 17140281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone 20-80 mg twice daily for chronic schizophrenia or schizoaffective disorder
Number of subjects: 0
Study 17140281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone for acute agitation
Number of subjects: 0
Study 17140281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone overall
Number of subjects: 0
Study 12773358 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored intervention for HIV prevention
Number of subjects: 0
Study 11382625 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 66
Study 11382625 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 66
Study 9402180 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM 1,200 mg/m2 + VNR 25 mg/m2
Number of subjects: 31
Study 9402180 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM 1,200 mg/m2 + VNR 20 mg/m2
Number of subjects: 31
Study 9402180 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM 1,000 mg/m2 + VNR 25 mg/m2
Number of subjects: 31
Study 9402180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 31
Study 8218536 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial induction consolidation chemotherapy for newly diagnosed AML
Number of subjects: 199
Study 2438841 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green argon laser treatment
Number of subjects: 71
Study 2438841 — intervention group
Group type: EXPERIMENTAL
Intervention: Red krypton laser treatment
Number of subjects: 71
Study 2438841 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 71
Study 29996886 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM intervention using the Flinders Program of chronic condition management (CCM)
Number of subjects: 300000
Study 29996886 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised yet flexible motivational process combined with evidence-based interventions
Number of subjects: 300000
Study 26898600 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management educational group program
Number of subjects: 475
Study 24199655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 536
Study 24199655 — intervention group
Group type: COMPARATOR
Intervention: No gastric lavage (Control)
Number of subjects: 536
Study 24199655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 536
Study 22592966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336
Study 21432590 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical activity (PA)
Number of subjects: 25
Study 21432590 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MTP)
Number of subjects: 25
Study 19720587 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD screening readiness measured by a three-item summative index
Number of subjects: 636
Study 19720587 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving knowledge about osteoporosis and BMD testing
Number of subjects: 636
Study 16054267 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (16 participants)
Number of subjects: 32
Study 16054267 — intervention group
Group type: COMPARATOR
Intervention: Elderly adults (16 participants)
Number of subjects: 32
Study 14511962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Number of subjects: 2219
Study 14511962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol only
Number of subjects: 2219
Study 14511962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Number of subjects: 2219
Study 14511962 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2219
Study 10389710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel
Number of subjects: 61
Study 10389710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10389710 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative fetal fibronectin test with 0.5 mg PGE2 gel
Number of subjects: 61
Study 8896855 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g EMLA cream
Number of subjects: 83
Study 8896855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 8896855 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 83
Study 1670586 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV), daily doses of IL-2 from 1.5 to 12 x 10(6) IU/m2
Number of subjects: 9
Study 1670586 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV), higher doses of IL-2
Number of subjects: 9
Study 1670586 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV)
Number of subjects: 9
Study 4072925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 to 50 mg/day)
Number of subjects: 551
Study 4072925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551
Study 4072925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 30306399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualistic intervention
Number of subjects: 180
Study 30306399 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive behavior
Number of subjects: 180
Study 30306399 — intervention group
Group type: COMPARATOR
Intervention: Cognitive load
Number of subjects: 180
Study 30306399 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 180
Study 30306399 — intervention group
Group type: EXPERIMENTAL
Intervention: Undirected movement
Number of subjects: 180
Study 30306399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of undirected movement and cognitive load
Number of subjects: 180
Study 27231927 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-delivered nutrition counseling intervention (10 hours over 6 months)
Number of subjects: 354
Study 27231927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 354
Study 24807391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission statin use
Number of subjects: 295
Study 24807391 — intervention group
Group type: COMPARATOR
Intervention: Statin-naive group
Number of subjects: 295
Study 20188847 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic theophylline (nonselective adenosine receptor antagonist)
Number of subjects: 0
Study 20188847 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine (local anesthetic)
Number of subjects: 0
Study 17674020 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT combined with intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 61
Study 17674020 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 61
Study 17674020 — intervention group
Group type: COMPARATOR
Intervention: PDT
Number of subjects: 61
Study 17954055 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 1053
Study 17954055 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 1053
Study 15502060 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled IV opioid analgesia (PCIA) with fentanyl
Number of subjects: 242
Study 15502060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.08% bupivacaine and fentanyl 1.6 microg/mL
Number of subjects: 242
Study 10904462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 224
Study 10904462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 9314296 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (arm A)
Number of subjects: 353
Study 9314296 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel (arm B)
Number of subjects: 353
Study 9314296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 353
Study 9314296 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel (GOG III)
Number of subjects: 353
Study 8349066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole, 40 mg per day (n = 31)
Number of subjects: 52
Study 8349066 — intervention group
Group type: COMPARATOR
Intervention: Injection therapy (adrenaline 1:10,000 plus polidocanol 1% injection associated with oral ranitidine 300 mg per day) (n = 21)
Number of subjects: 52
Study 8349066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 3538488 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% oxygen
Number of subjects: 19
Study 3538488 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 19
Study 3538488 — intervention group
Group type: COMPARATOR
Intervention: Air delivered from a cylinder
Number of subjects: 19
Study 31401045 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pamphlet and slideshow
Number of subjects: 48
Study 31401045 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 48
Study 31401045 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP use (in both groups)
Number of subjects: 48
Study 28419997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating leptin levels
Number of subjects: 0
Study 28419997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted soluble plasma leptin receptor (sOB-R) levels
Number of subjects: 0
Study 26332539 — intervention group
Group type: EXPERIMENTAL
Intervention: USL261 (2.5, 5.0, and 7.5 mg)
Number of subjects: 25
Study 26332539 — intervention group
Group type: COMPARATOR
Intervention: MDZ-inj IN (5.0 mg)
Number of subjects: 25
Study 26332539 — intervention group
Group type: COMPARATOR
Intervention: MDZ-inj IV (2.5 mg)
Number of subjects: 25
Study 24172626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye drops
Number of subjects: 33
Study 24172626 — intervention group
Group type: COMPARATOR
Intervention: Systemic peroral antibiotics
Number of subjects: 33
Study 21444869 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Number of subjects: 356
Study 21444869 — intervention group
Group type: COMPARATOR
Intervention: 4-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Number of subjects: 356
Study 19490278 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth in foster care
Number of subjects: 56
Study 19490278 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adolescents and those in relative placement
Number of subjects: 56
Study 19490278 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth in group homes, those who experienced parental death, or had a history of physical/emotional abuse or attempted suicide
Number of subjects: 56
Study 16865997 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik Sensonic
Number of subjects: 144
Study 16865997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite
Number of subjects: 144
Study 16865997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B Sonic Complete
Number of subjects: 144
Study 16865997 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Indicator (manual)
Number of subjects: 144
Study 12953289 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (IgG) enzyme‐linked immunosorbent assay (ELISA) for measuring serum antibody concentrations
Number of subjects: 0
Study 12953289 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control methodology in ELISA
Number of subjects: 0
Study 11062357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN; 10 mg/day) for 2 years
Number of subjects: 53
Study 11062357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN; 10 mg/day) for 3 years
Number of subjects: 53
Study 9425591 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with a mixture of multiple allergen extracts
Number of subjects: 121
Study 9425591 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 121
Study 9425591 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy using synthetic fragments of the major allergen responsible for allergic reactions to cats
Number of subjects: 121
Study 8375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 96
Study 8375429 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine-levodopa combination therapy
Number of subjects: 96
Study 3758170 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4, 1.2, 3.6, 10.8, 32.4, 97.2 mg)
Number of subjects: 2
Study 3758170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Dextrose 5% in water)
Number of subjects: 2
Study 3758170 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 2
Study 30721950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized P4 (3 × 200 mg/d IM)
Number of subjects: 40
Study 30721950 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (5 mg IM) and oral placebo
Number of subjects: 40
Study 30721950 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 IM and oral micronized P4
Number of subjects: 40
Study 28397581 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab plus native vitamin D
Number of subjects: 56
Study 28397581 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab plus ELD
Number of subjects: 56
Study 26456492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-elastic bougie (GEB) during chest compressions
Number of subjects: 17
Study 26456492 — intervention group
Group type: COMPARATOR
Intervention: No gum-elastic bougie (without GEB) during chest compressions
Number of subjects: 17
Study 26456492 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB during chest compressions
Number of subjects: 17
Study 26456492 — intervention group
Group type: COMPARATOR
Intervention: No GEB during chest compressions
Number of subjects: 17
Study 24903517 — intervention group
Group type: EXPERIMENTAL
Intervention: Regret model
Number of subjects: 41
Study 24903517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-processing model
Number of subjects: 41
Study 22016074 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 1530
Study 22016074 — intervention group
Group type: COMPARATOR
Intervention: Shock-only
Number of subjects: 1530